Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Oct. 4, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Global & USA BioSimilar ... The highly awaited US Biosimilar market will ... awaited filigrastim biologic, Zarxio. How will the global market ... author reveals that biosimilars could save the US economy ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic ... complete healing of an otherwise non-healing surgical knee wound. , The case involved ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... 2015 GlassesOff (OTCBB: GLSO), a visual ... the human vision system, announced today a partnership with eight-time ... Chris Paul to develop a new mobile app designed ... their real-life on-court performance. Vision is the inception ... shooting a ball or blocking a pass. The critical impact ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... , ,So how many boards can you break with one ... you juggle at one time? Even more important what projects ... improve your organizations position in the marketplace? If not, read on, ... is a program of continuous improvement that focuses on customer requirements. ...
... Wis. Whenever a new piece of technology comes out ... an instant success. More frequently, it is seen as an ... adopters, who are often making a risky gamble. To become ... field, tested in real-world conditions and purchased enough so early ...
... Quintessence Biosciences, Inc. has formed a scientific ... of cancer therapeutics. , ,Announced last week by ... the board will consist of distinguished scientific leaders who ... Quintessence Biosciences, Inc. They will also assist the company ...
Cached Biology Technology:Part 6 Project Performance Get on the path to continuous improvement 2Part 6 Project Performance Get on the path to continuous improvement 3Part 6 Project Performance Get on the path to continuous improvement 4Laying the foundation for RFID 2Laying the foundation for RFID 3Laying the foundation for RFID 4Quintessence Biosciences forms cancer therapeutic advisory board 2
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... A tiny difference in the coding pattern of a single ... drops with advancing age, investigators at the Stanford University School ... System have learned. In a study to be published ... tested the skills of experienced airplane pilots and found that ...
... eaten from silverware or worn copper jewelry, you,ve been ... into the environment, say scientists at the University of ... and the public have been concerned that the potential ... way of environmental exposure. Now, with the ...
... available in Spanish . The study, ... the result of an interdisciplinary collaboration between two researchers: one ... the area of geographic history under the direction of the ... is Consejo Superior de Investigaciones Cientficas (CSIC Spanish National ...
Cached Biology News:Gene variation predicts rate of age-related decline in mental performance, Stanford study 2Gene variation predicts rate of age-related decline in mental performance, Stanford study 3Gene variation predicts rate of age-related decline in mental performance, Stanford study 4Nanoparticles and their size may not be big issues 2Forest fires are becoming larger and more frequent 2
... Chromo4 real-time PCR detector is an optical ... a DNA Engine or Dyad Disciple gradient-capable ... a compact scanning photonics shuttle that contains ... 500-535 nm, 555-585 nm, 620-650 nm) and ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
... four slides. The new ArraySlide 24-4 chamber ... x 7mm) individual printing surfaces for multiple ... studies. Unlike other systems, this device utilizes ... of contaminating adhesives. The chamber itself is ...
... x 3 nmol (individual) with sequence ... specifically targeted to your target gene of interestis ... you get more than 75% knockdown of your ... nM siRNA for transfection and confirmation of optimal ...
Biology Products: